The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boytsov S.A.

National Medical Research Centre of Cardiology named after academician E.I. Chazov

Vavilova T.V.

V.A. Almazov National Medical Research Center

Gurevich V.S.

Saint Petersburg University

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Drozdova L.Yu.

National Medical Research Center for Therapy and Preventive Medicine

Yezhov M.V.

National Medical Research Centre of Cardiology named after academician E.I. Chazov

Zvartau N.E.

V.A. Almazov National Medical Research Center

Sergienko I.V.

National Medical Research Centre of Cardiology named after academician E.I. Chazov

The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts

Authors:

Boytsov S.A., Vavilova T.V., Gurevich V.S., Drapkina O.M., Drozdova L.Yu., Yezhov M.V., Zvartau N.E., Sergienko I.V.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2025;28(4): 7‑15

DOI: 10.17116/profmed2025280417

Read: 2130 times

Download PDF (RU)
Contact the author
Table of contents

THE PLACE OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND TRIGLYCERIDES IN THE ASSESSMENT OF CARDIOVASCULAR RISK: RESOLUTION OF THE PANEL OF EXPERTS
THE PLACE OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND TRIGLYCERIDES IN THE ASSESSMENT OF CARDIOVASCULAR RISK: RESOLUTION OF THE PANEL OF EXPERTS

To cite this article:

Boytsov SA, Vavilova TV, Gurevich VS, et al. The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts. Russian Journal of Preventive Medicine. 2025;28(4):7‑15. (In Russ.)
https://doi.org/10.17116/profmed2025280417

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Creating an index reflexing cardiovascular risk using the vital functions inte­gral analysis. Russian Journal of Preventive Medi­cine. 2025;(4):82-88
Neutrophil elastase as a promising biomarker of low-grade inflammation in chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(4):142-148
Increased expression of circular RNA circSPARC and circTMEM181 in coro­nary athe­rosclerosis. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):24-29
Prevalence and role of elevated serum lipo­protein(a) in patients with myocardial infa­rction acco­rding to the Russian regi­ster of acute myocardial infa­rction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48
The influence of demo­graphic factors and major como­rbidities on serum circulating regu­latory microRNAs in patients with coro­nary artery athe­rosclerosis and thoracic aortic aneurysm: a single-center cohort study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):174-182
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Two years expe­rience of using alirocumab in patients with dyslipidemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):216-220
QRISK-3 cardiovascular risk asse­ssment algo­rithm in prediction of kidney transplantation outcomes. Russian Cardiology Bulletin. 2025;(2):61-69
Features of care of patients with cardiovascular diseases and cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):99-104
Abstract:

The main focus for reducing the incidence of cardiovascular diseases (CVD) associated with atherosclerosis is early stratification of the CVD risk, timely detection of lipid metabolism disorders, and medical care for patients with a high and very high risk of developing such diseases. High-density lipoprotein cholesterol (HDL-C) was previously considered a risk factor for atherosclerosis; however, recently, high triglycerides and non-high-density lipoprotein cholesterol (NHDL-C) have also become important risk factors. This Resolution of the Panel of Experts reflects the roles of triglycerides and non-HDL cholesterol in cardiovascular risk assessment.

Keywords:

lipid metabolism disorders
hypertriglyceridemia
atherosclerosis
triglyceride-rich particles
cardiovascular risk

Authors:

Boytsov S.A.

National Medical Research Centre of Cardiology named after academician E.I. Chazov

Vavilova T.V.

V.A. Almazov National Medical Research Center

Gurevich V.S.

Saint Petersburg University

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine;
A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Drozdova L.Yu.

National Medical Research Center for Therapy and Preventive Medicine

Yezhov M.V.

National Medical Research Centre of Cardiology named after academician E.I. Chazov

Zvartau N.E.

V.A. Almazov National Medical Research Center

Sergienko I.V.

National Medical Research Centre of Cardiology named after academician E.I. Chazov

Received:

22.01.2025

Accepted:

17.03.2025

Close metadata

References:

  1. Kontsevaya AN, Drapkina OM, Balanova YuA, et al. Economic burden of cardiovascular diseases in the Russian Federation in 2016. Racional’naja farmakoterapija v kardiologii. 2018;14(2):156-166. (In Russ.). https://doi.org/10.20996/1819-6446-2018-14-2-156-166
  2. The Prevention Paradox. Health Knowledge. Accessed March 18, 2025. https://www.healthknowledge.org.uk/public-health-textbook/disease-causation-diagnostic/2h-principles-health-promotion/prevention-paradox
  3. Lindbohm JV, Sipilä PN, Mars NJ, et al. 5-year versus risk-category-specific screening intervals for cardiovascular disease prevention: a cohort study. Lancet. Public Health. 2019;4(4):e189-e199. https://doi.org/10.1016/S2468-2667(19)30023-4
  4. Vilaplana-Carnerero C, Giner-Soriano M, Dominguez À, et al. Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review. Biomedicines. 2023;11(4):1206. https://doi.org/10.3390/BIOMEDICINES11041206
  5. Ahmadi A, Stone GW, Leipsic J, et al. Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease. Circulation Research. 2016;119(2):317-329.  https://doi.org/10.1161/CIRCRESAHA.116.308952
  6. Calais F, Eriksson Östman M, Hedberg P, et al. Incremental prognostic value of coronary and systemic atherosclerosis after myocardial infarction. International Journal of Cardiology. 2018;261:6-11.  https://doi.org/10.1016/j.ijcard.2018.02.035
  7. Hoshino T, Sissani L, Labreuche J, et al. Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease. JAMA Neurology. 2018;75(2):203-211.  https://doi.org/10.1001/JAMANEUROL.2017.3960
  8. Erina AM, Usoltsev DA, Boyarinova MA, et al. Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). Rossijskij kardiologicheskij zhurnal. 2022;27(5):5006. (In Russ.). https://doi.org/10.15829/1560-4071-2022-5006
  9. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855): 524-533.  https://doi.org/10.1038/s41586-021-03392-8
  10. Fan J, Watanabe T. Atherosclerosis: Known and unknown. Pathology International. 2022;72(3):151-160.  https://doi.org/10.1111/pin.13202
  11. Visseren FLJ, MacH F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;43(42):4468. https://doi.org/10.1093/EURHEARTJ/EHAB484
  12. Sergiyenko IV. Russian clinical guidelines on lipid metabolism disorders 2024. What’s new? RMZh. 2023;4:12-16. (In Russ.).
  13. Raja V, Aguiar C, Alsayed N, et al. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis. 2023; 383:117312. https://doi.org/10.1016/j.atherosclerosis.2023.117312
  14. Boskovic N, Giga V, Djordjevic-Dikic A, et al. Comparison of SCORE and SCORE 2 risk prediction tools in contemporary very high risk european population. European Heart Journal. 2022;43:2281. https://doi.org/10.1093/EURHEARTJ/EHAC544.2281
  15. Graham IM, Di Angelantonio E, Huculeci R, et al. New Way to «SCORE» Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines. Current Cardiology Reports. 2022;24(11): 1679-1684. https://doi.org/10.1007/S11886-022-01790-6
  16. Graham IM, Di Angelantonio E, Visseren F, et al. Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. Journal of the American College of Cardiology. 2021;77(24):3046-3057. https://doi.org/10.1016/J.JACC.2021.04.052
  17. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal. 2021;42(25): 2439-2454. https://doi.org/10.1093/EURHEARTJ/EHAB309
  18. Raja V, Aguiar C, Alsayed N, et al. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis. 2023; 383:117312. https://doi.org/10.1016/j.atherosclerosis.2023.117312
  19. Tregubov AV, Tregubova AA, Alekseeva IV, et al. Comparison of the results of cardiovascular risk assessment using the SCORE and SCORE2 scales. Ateroskleroz i dislipidemii. 2022;3:41-47. (In Russ.). https://doi.org/10.34687/2219-8202.JAD.2022.03.0005
  20. Duffy EY, Ashen D, Blumenthal RS, et al. Communication approaches to enhance patient motivation and adherence in cardiovascular disease prevention. Clinical Cardiology. 2021;44(9):1199-1207. https://doi.org/10.1002/CLC.23555
  21. Erina AM, Usoltsev DA, Boyarinova MA, et al. Appointment of lipid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). Rossijskij kardiologicheskij zhurnal. 2022;27(5):5006. (In Russ.). https://doi.org/10.15829/1560-4071-2022-5006
  22. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000. https://doi.org/10.1001/JAMA.2009.1619
  23. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-188.  https://doi.org/10.1093/EURHEARTJ/EHZ455
  24. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
  25. Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28(8):1916-1921. https://doi.org/10.2337/DIACARE.28.8.1916
  26. Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? Journal of the American College of Cardiology. 2009;55(1):42-44.  https://doi.org/10.1016/J.JACC.2009.07.056
  27. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Archives of Internal Medicine. 2001;16(11)1:1413-1419. https://doi.org/10.1001/ARCHINTE.161.11.1413
  28. Kastelein JJP, Van Der Steeg WA, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002-3009. https://doi.org/10.1161/CIRCULATIONAHA.107.713438
  29. Wongcharoen W, Sutthiwutthichai S, Gunaparn S, et al. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol?: A retrospective study. BMC Cardiovascular Disorders. 2017;17(1):10.  https://doi.org/10.1186/S12872-016-0450-9
  30. Brunner FJ, Waldeyer C, Ojeda F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019;394:2173. https://doi.org/10.1016/S0140-6736(19)32519-X
  31. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of Atherosclerosis. International Journal of Molecular Sciences. 2022; 23(6):3346. https://doi.org/10.3390/IJMS23063346
  32. ESC. Early detection of cardiovascular disease — the future of cardiology? An article from the e-journal of the ESC. Council for Cardiology Practice. 2006;4(19). Accessed March 18, 2025. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-4/vol4n19-Title-Early-detection-of-cardiovascular-disease-the-future-of-cardi
  33. Navar AM, Fine LJ, Ambrosius WT, et al. Earlier treatment in adults with high lifetime risk of cardiovascular diseases: What prevention trials are feasible and could change clinical practice? Report of a National Heart, Lung, and Blood Institute (NHLBI) Workshop. American Journal of Preventive Cardiology. 2022;12:100430. https://doi.org/10.1016/J.AJPC.2022.100430
  34. Ivey SL, Hanley HR, Taylor C, et al. Early identification and treatment of women’s cardiovascular risk factors prevents cardiovascular disease, saves lives, and protects future generations: Policy recommendations and take action plan utilizing policy levers. Clinical Cardiology. 2022;45:1100-1106. https://doi.org/10.1002/CLC.23921
  35. Vsemirnaya organizaciya zdravooxraneniya. Programmy` skrininga: kratkoe rukovodstvo. Povy`shenie e`ffektivnosti, maksimal`noe uvelichenie pol`zy` i minimizaciya vreda. 2023. (In Russ.).
  36. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-485.  https://doi.org/10.1161/01.CIR.60.3.473
  37. Sniderman AD, Couture P, Martin SS, et al. Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. Journal of Lipid Research. 2018;59(7):1266-1275. https://doi.org/10.1194/JLR.R082271
  38. Pradhan A, Bhandari M, Vishwakarma P, et al. Triglycerides and Cardiovascular Outcomes — Can We reduce-it ? International Journal of Angiology. 2020;29(1):2-11.  https://doi.org/10.1055/S-0040-1701639
  39. Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nature Reviews Cardiology. 2017;14:401-411.  https://doi.org/10.1038/nrcardio.2017.31
  40. Narusheniya lipidnogo obmena. Klinicheskie rekomendacii. Accessed March 18, 2025. (In Russ.). https://cr.minzdrav.gov.ru/recomend/752_1
  41. Halcox JP, Banegas JR, Roy C, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovascular Disorders. 2017;17(1):160.  https://doi.org/10.1186/S12872-017-0591-5
  42. Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Russian Journal of Preventive Medicine. 2016;19(1):15-23. (In Russ.). https://doi.org/10.17116/profmed201619115-23
  43. Shalnova SA, Deev AD, Metelskaya VA, et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: The study ESSE-RF. Kardiovaskuljarnaja terapija i profilaktika. 2016;15(4):29-37. (In Russ.). https://doi.org/10.15829/1728-8800-2016-4-29-37
  44. Lu W, Pikhart H, Tamosiunas A, et al. Prevalence, awareness, treatment and control of hypertension, diabetes and hypercholesterolemia, and associated risk factors in the Czech Republic, Russia, Poland and Lithuania: a cross-sectional study. BMC Public Health. 2022;22(1):883.  https://doi.org/10.1186/S12889-022-13260-3/FIGURES/3
  45. Akhmedzhanov N. Dyslipidemia 2022: how to reduce risk and achieve goals: lecture review. Lvrach.ru. Accessed March 18, 2025. (In Russ.). https://www.lvrach.ru/partners/rosulip_plus/15438371
  46. Ezhov MV, Barbarash OL, Voevoda MI, et al. Organization of lipid centers operation in the Russian Federation — new opportunities. Rossijskij kardiologicheskij zhurnal. 2021;26(6):4489. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4489
  47. Sadovnikov PS, Olkhovik AYu, Gurevich VS. Calculation method for the low-density lipoprotein cholesterol levels on the basis of the lipid metabolism modern paradigm. Ateroskleroz i dislipidemii. 2022;3:21-28. (In Russ.). https://doi.org/10.34687/2219-8202.JAD.2022.03.0003
  48. Csenteri O, Jancsó Z, Szöllösi GJ, et al. Differences of cardiovascular risk assessment in clinical practice using SCORE and SCORE2. Open Heart. 2022;9(2):e002087. https://doi.org/10.1136/OPENHRT-2022-002087
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.